BEAM
Beam Therapeutics Inc

6,249
Mkt Cap
$2.13B
Volume
1.62M
52W High
$35.25
52W Low
$13.53
PE Ratio
-4.73
BEAM Fundamentals
Price
$20.60
Prev Close
$20.98
Open
$21.40
50D MA
$24.45
Beta
1.90
Avg. Volume
2.55M
EPS (Annual)
-$4.58
P/B
2.20
Rev/Employee
$131,507.25
Loading...
Loading...
News
all
press releases
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Rating of "Moderate Buy" by Analysts
Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the fourteen ratings firms that are currently covering the firm, Marketbeat...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Fox Run Management L.L.C. Takes Position in Beam Therapeutics Inc. $BEAM
Fox Run Management L.L.C. acquired a new position in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange...
MarketBeat·6d ago
News Placeholder
Beam Therapeutics (NASDAQ:BEAM) Trading 6.7% Higher - Here's Why
Beam Therapeutics (NASDAQ:BEAM) Shares Up 6.7% - Still a Buy...
MarketBeat·6d ago
News Placeholder
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.
Zacks·6d ago
News Placeholder
Vestmark Advisory Solutions Inc. Has $5.49 Million Stock Holdings in Beam Therapeutics Inc. $BEAM
Vestmark Advisory Solutions Inc. raised its position in shares of Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 109.0% in the 2nd quarter, according to the company in its most recent Form 13F...
MarketBeat·11d ago
News Placeholder
Cantor Fitzgerald Has Weak Forecast for BEAM FY2025 Earnings
Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of Beam Therapeutics in a...
MarketBeat·12d ago
News Placeholder
What is HC Wainwright's Estimate for BEAM FY2025 Earnings?
Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Stock analysts at HC Wainwright lowered their FY2025 earnings estimates for Beam Therapeutics in a report issued on Wednesday, November 5th. HC...
MarketBeat·12d ago
News Placeholder
FY2025 Earnings Forecast for BEAM Issued By Leerink Partnrs
Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Investment analysts at Leerink Partnrs lowered their FY2025 earnings per share estimates for shares of Beam Therapeutics in a research report...
MarketBeat·12d ago
News Placeholder
Wall Street Zen Downgrades Beam Therapeutics (NASDAQ:BEAM) to Sell
Wall Street Zen cut shares of Beam Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·13d ago
News Placeholder
Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y
RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs.
Zacks·15d ago

Latest BEAM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.